Abstracts tagged "autoimmune diseases"

Abstract Number: 0930 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Ryan Camire¹, Yi Zhang², Virginia Massa², Jordan Leedberg², Erik Corcoran², Emily Lurier², Chris Carroll², Chris Ho², Dapeng Chen², Bradley Enerson², Revonda Mehovic², Ziyan Zhao², Lincoln Howarth², Susanne Breitkopf², Sarah Martinez², Melissa Ford², Xue Fei², Murugappan Sathappa², Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³, Nello Mainolfi⁴ and Veronica Campbell², ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5, an undrugged transcription factor, is an autoimmune susceptibility gene that has been linked to RA and other autoimmune diseases including SLE, Sjögren’s, and…
Abstract Number: 0897 • ACR Convergence 2025
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
william Galbavy, Hyunjin Kim, Brian Klotz, Marine Malbec, Carley Tasker, Eva Conde, Andrea Vecchione, Seblewongel Asrat, Benjamin Daniel, Weikeat Lim, Andre Limnander and Jamie Orengo, Regeneron, Tarrytown, NY
Background/Purpose: Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED) is a rare syndrome of multi-organ autoimmunity driven by the presence of self-reactive T cells and autoantibodies caused…
Abstract Number: 0887 • ACR Convergence 2025
Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
Runci Wang¹, Chunyan Xiang², Adrien Procureur³, Julian Sanchez-Dal Cin³, Qing Wang⁴, Xinyue Lian⁵, Michelle Rosenzwajg³, Yves Allenbach⁶, Deepak Rao⁷, Qiong Fu⁸, Nan Shen⁹, Joe-Elie Salem³ and Shuang Ye¹⁰, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), shanghai, China (People's Republic), ³Sorbonne Université, Paris, France, ⁴Zhongshan Hospital, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, China (People's Republic), ⁶SORBONNE UNIVERSITE, Paris, France, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Renji Hospital, Shanghai, Shanghai, China, ⁹Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ¹⁰Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies for cancer can induce immune-related adverse events (irAEs) involving musculoskeletal (MSK) systems. ICI myotoxicity (ICI-M) can present as a…
Abstract Number: 0485 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Rheumathoid Arthritis (RA) is a chronic inflammatory disease that affects the musculoskeletal system. Early and effective treatment is important to improve the quality of…
Abstract Number: 0285 • ACR Convergence 2025
Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
Connor Buechler¹, Nawang Singhe², Lindsey Wanberg², Cody Rasner², Joseph McGrath², Karen Baker-James², Rebecca Freese² and David Pearson³, ¹University of Minnesota, Mendota Heights, MN, ²University of Minnesota, Minneapolis, MN, ³Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Amyopathic dermatomyositis (ADM) is a subset of DM in which cutaneous findings occur without muscle disease for >6 months after diagnosis. However, there is…
Abstract Number: 0246 • ACR Convergence 2025
Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
Marco Di Paola¹, Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Chiara Stomaci⁷, Roberto Franchini¹, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Envinronmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Intestinal Bowel Diseases (IBD), including Crohn’s (ChD), and Ulcerative Colitis (UCD), along with Celiac (ClD), diseases are chronic inflammatory conditions that primarily affect the…
Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Santiago Dans Caballero¹, Massimo Radin², Chary López pedrera³, MARIA ANGELES AGUIRRE ZAMORANO⁴, Christian Merlo-Ruiz⁵, Ismael Sanchez-Pareja⁴, Irene Cecchi⁶ and Savino Sciascia⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²University of Turin, Turin, Turin, Italy, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁶University of Turin, Turin, Piemonte, Italy, ⁷University of Turin, Torino, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…
Abstract Number: 0024 • ACR Convergence 2025
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Daniel Panyard¹, Daniel Li², Pik Fang Kho², Rodrigo Guarischi-Sousa³, Jiayan Zhou², Austin Hilliard⁴, Christie Bartels⁵, Philip Tsao² and Themistocles Assimes², ¹Stanford University, Sunnyvale, CA, ²Stanford University, Palo Alto, CA, ³Palo Alto Veterans Institute for Research, Palo Alto, CA, ⁴VA Palo Alto Health Care, Palo Alto, CA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
Abstract Number: 2641 • ACR Convergence 2025
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Ricardo Grieshaber-Bouyer¹, Jamie Haddon², Maria Gabriella Raimondo³, Carlo Tur³, Sebastian Böltz³, Tobias Dashi⁴, Melanie Hagen⁵, Andreas Wirsching³, Tobias Rathe⁴, Xuan Wu⁶, Peter Wung², Francis Kim², Yonghong Zhu⁶, Ken Song², Timothy Lu⁷ and Georg Schett⁸, ¹University Hospital Erlangen, Erlangen, Germany, ²Candid Therapeutics, San Diego, CA, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine ³- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ⁶EpimAb Biotherapeutics, Shanghai, China (People's Republic), ⁷Candid Therapeutics, San Diego, ⁸Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
Abstract Number: 2538 • ACR Convergence 2025
Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Carmen Lasa Teja⁵, Elena Aurrecoechea⁶, Diana Prieto-Peña⁷ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ⁶Hospital Sierrallana, CANTABRIA, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision…
Abstract Number: 2417 • ACR Convergence 2025
Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls
Rammohan Mylavarapu¹, Meghna Gavali², Bansi Kashyap Parijeya³, Kaushik Puranam⁴ and Liza rajasekhar⁵, ¹NIZAMS INSTITUTE OF MEDICAL SCIENCES, Hyderabad, Telangana, India, ²nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ³Synergy superspeciality hospital, Rajkot, Gujarat, India, ⁴Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, ⁵Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) are a heterogeneous group of disorders marked by the presence of antinuclear antibodies (ANA), commonly detected by HEp-2 cell-based…
Abstract Number: 2050 • ACR Convergence 2025
Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis
Sri Laxmi Priya Sunkara¹, Ravi Medarametla², Anjani Mahesh Kumar Cherukuri³, Rithish Nimmagadda⁴, Kaksha Parrikh⁵, Punith Chirumamilla⁶, Pranathi Bandarupalli⁷, Manoja Gullapalli⁸ and Naga Alekhya Garikipati⁹, ¹White river medical center, batesville, AR, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Guntur Medical College, Guntur, Andhra Pradesh, India, ⁴One Brooklyn Health, New York, NY, ⁵Atlanticare regional medical center, New Jersey, ⁶Baptist Memorial Hospital North Mississippi, Oxford, MS, ⁷Mercy St Vincent Medical Center, Toledo, OH, ⁸University of Arkansas for Medical Sciences, Little Rock, AR, ⁹Mediciti Institute Of Medical Sciences, Hyderabad, India
Background/Purpose: Autoimmune–associated interstitial lung disease (A‑ILD) which includes Rheumatoid arthritis associated interstitial lung disease (RA-ILD), Systemic Sclerosis associated interstitial lung disease (SS-ILD), and others is…
Abstract Number: 1869 • ACR Convergence 2025
A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease
Olga Sanchez Pernaute¹, Mª Jesus Rodriguez-Nieto², Cristina Vadillo Font³, Maria asuncion Nieto³, Laura Cebrian⁴, Belen Lopez Muñiz⁵, Hilda Godoy Tundidor⁶, Rosalia Laporta⁷, Jesus Loarce Martos⁸, Juan A Rigual⁸, fredeswinda Romero-Bueno⁹, Irene Llorente Cubas¹⁰, Claudia Valenzuela¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁸, Jose Luis Morell Hita⁸ and lydia Abasolo Alcazar¹⁴, ¹Clinica Universidad de Navarra, Madrid, Madrid, Spain, ²Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ³Hospital Clínico S Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Infanta Leonor, Madrid, Spain, ⁶Hospital Universitario puerta de hierro, Madrid, Spain, ⁷Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Patients with interstitial lung disease associated to a connective tissue disease (CTD-ILD) are a heterogeneous population both concerning mechanisms and trajectories. In an RNA…
Abstract Number: 1728 • ACR Convergence 2025
Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Jiana Chen¹, Jiaqi Xu¹, Ziyue Zhou², Xu Jiang¹ and Huaxia Yang¹, ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ¹⁰⁰⁷³⁰, Beijing, China, Beijing, China (People's Republic), ²peiking meidical, beijing
Background/Purpose: Immune checkpoint inhibitors (ICIs), while revolutionary in cancer treatment, may induce severe or even fatal immune-related adverse event (irAE). The mechanisms underlying irAE development…
Abstract Number: 1547 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Blanca Garcia-Magallon², Deseada Palma-Sanchez³, Andrea García-Valle⁴, Irati Urionaguena Onaindia⁵, Adrián Mayo-Juanatey⁶, Paúl Hernández Velasco⁷, GUILLERMO GONZALEZ ARRIBAS⁸, Ana Pareja-Martínez⁹, Montserrat Corteguera¹⁰, Guillen Sada Urmeneta¹¹, Paz Collado Ramos¹², Jose Luis Tandaipan¹³, Juan Roberto Miguelez Sanchez¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Rheumatology. Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ⁴Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁵Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ⁶Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁷Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ⁸Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ⁹Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, ¹⁰Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ¹¹Rheumatology. Hospital Reina Sofía, Tudela, Navarra, Spain, ¹²Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ¹³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain
Background/Purpose: Lupus Nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), occurring in up to 50% of patients. Currently, Anifrolumab (ANI) is approved…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].